David A. Weber

Dr. Weber has served as Otonomy’s president and chief executive officer and on our board of directors since November 2010. Prior to joining the company, he served from February 2004 to April 2010 as the chief executive officer of MacuSight, Inc., a developer of a sustained-delivery formulation of sirolimus for the treatment of severe ophthalmic diseases.

Prior to MacuSight, Dr. Weber served as acting chief executive officer and executive vice president of Oculex Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of intraocular pharmaceuticals and drug delivery systems, until its acquisition by Allergan in 2003.

Dr. Weber has also held management positions with Oral-B Laboratories, a developer and manufacturer of oral hygiene products, and with Procter & Gamble, Co., a consumer products company. Dr. Weber received his doctorate in medical microbiology from Creighton University and his master’s degree and bachelor’s degree in biological sciences from Wichita State University.

David A. Weber is the CEO & President at Otonomy, based in United States, North America. With a background in Biotechnology, David A. Weber has a rich history of leadership and innovation.David A. Weber studied Bachelors Biological Sciences at Wichita State University. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.